Moreover, an increased severity is associated with anti-CTLA-4 therapy in addition to an increased incidence of all extraintestinal manifestations including mouth ulcers, anal fissures, and esophagitis/gastritis (19). This evidence concerns the gene CTLA4 and esophagitis.